retatrutide clinical results 💊🔥 Retatrutide: The Most Powerful Weight-Loss Drug Yet? 🧬📊 New Phase 3 are turning heads retatrutide, a next-generation triple-agonist targeting GLP-1, GIP and glucagon receptors, is showing unmatched levels of Retatrutide clinical trial done! Now

PlexusDx makes semaglutide accessible at $149 per month, with no insurance requirement and HSA/FSA eligibility, so cost is not a barrier to treatment once you and your doctor decide the timing is right

The net result depends on dose, duration, and individual genetics, but steroid-induced weight gain can partially offset semaglutide benefits

Rakhra V, Galappaththy SL, Bulchandani S, Cabandugama PK

GLP-1 Vision Loss Lawsuits In January, the same judge was also put in charge of a growing number of GLP-1 vision loss lawsuits, a smaller, but growing, litigation that began after a series of studies linked semaglutide-based drugs, like Ozempic, Wegovy and Rybelsus, to being associated with a condition known as non-arteritic anterior ischemic optic neuropathy (NAION)

Ghrelin Modulates Brain Activity in Areas that Control Appetitive Behavior